Table 6.
Haplotype analysis of AITDs patients and controls
| Haplotype | Controls (Frequency) | AITD | P | OR (95% CI) | GD (Frequency) | P | OR (95% CI) | HT (Frequency) | P | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Block 1 | ||||||||||
| AT | 952(53.3) | 1010(49.4) | 0.016 | 0.856 | 644(47.9) | 0.003 | 0.806 (0.699-0.929) | 366(52.2) | 0.626 | - |
| 0.754-0.972 | ||||||||||
| GC | 663(37.2) | 795(38.9) | 0.265 | - | 536(39.9) | 0.116 | - | 259(37.0) | 0.955 | - |
| GT | 160(8.9) | 223(11.0) | 0.045 | 1.245 | 149(11.1) | 0.048 | 1.267 (1.001-1.603) | 74(10.6) | 0.215 | - |
| 1.005-1.541 | ||||||||||
| Block 2 | ||||||||||
| GG | 1079(60.5) | 1188(58.2) | 0.136 | 774(57.7) | 0.105 | - | 414(59.1) | 0.519 | - | |
| AA | 703(39.5) | 854(41.8) | 0.136 | 568(42.3) | 0.105 | - | 286(40.9) | 0.519 | - |
AITDs, autoimmune thyroid diseases; GD, Graves’ disease; HT, Hashimoto’s thyroiditis; OR, odds ratio; CI, confidence interval.